Tamoxifen and the Risk of Ovarian Cancer in BRCA1 Mutation Carriers

OBJECTIVE: BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Vicus, Danielle, Rosen, Barry, Lubinski, Jan, Domchek, Susan, Kauff, Noah D., Lynch, Henry T., Isaacs, Claudine, Tung, Nadine, Sun, Ping, Narod, Steven A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3756313/
https://ncbi.nlm.nih.gov/pubmed/19577280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2009.06.012
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky